title: Overview of the clinical evidence for the use of NovaMin in providing relief from the pain of dentin hypersensitivity.
abstract: Dentin hypersensitivity is a common condition that affects the adult population worldwide. NovaMin is technically described as amorphous sodium calcium phosphosilicate, and has been shown in laboratory studies to rapidly occlude dentin tubules and form a protective hydroxyapatite-like layer on the dentin surface. A number of clinical studies investigating the efficacy of NovaMin for the relief of pain from dentin hypersensitivity have been conducted in the United States, Ireland, China, and India. This article reviews the available literature and finds support based on randomized controlled clinical trials for the use of NovaMin in anhydrous toothpaste formulations in providing relief of pain from dentin hypersensitivity.
authors: GlaxoSmithKline Consumer Healthcare Weybridge, Surrey, UK.
authors: Linda
authors: L
authors: Gendreau
authors: Ashley P S
authors: AP
authors: Barlow
authors: Stephen C
authors: SC
authors: Mason
mesh_terms: D002130:Calcium Phosphates / Q000737:chemistry / Q000627:therapeutic use; D002327:Cariostatic Agents / Q000627:therapeutic use; D003804:Dentin / Q000187:drug effects / Q000648:ultrastructure; D057133:Dentin Desensitizing Agents / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000188:drug therapy*; D017886:Durapatite / Q000737:chemistry; D005459:Fluorides / Q000627:therapeutic use; D005898:Glass / Q000737:chemistry; D006801:Humans; D010710:Phosphates / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017640:Silicates / Q000737:chemistry / Q000627:therapeutic use; D014100:Toothpastes / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002130:Calcium Phosphates; D002327:Cariostatic Agents; D057133:Dentin Desensitizing Agents; C510984:NovaMin; D010710:Phosphates; D017640:Silicates; D014100:Toothpastes; C012980:fluorophosphate; C076375:rhenanite; D017886:Durapatite; D005459:Fluorides